National Health Insurance Administration: By the end of June 2026, at least 100 key monitored easy-to-divert and resell drugs will be included in the intelligent supervision coverage.

On November 3rd, the Office of the National Medical Security Administration issued a notice on further strengthening the intelligent supervision of overprescribing. The notice mentions the implementation of pilot projects and the exploration of experiences. By the end of December 2025, in the national intelligent supervision reform pilot areas, at least 50 key monitored medications prone to resale and flow back into the medical insurance system will be included in the intelligent supervision coverage. This will be gradually expanded to cover the entire province. By the end of June 2026, at least 100 key monitored medications prone to resale and flow back into the medical insurance system will be included in the intelligent supervision coverage in all provinces, autonomous regions, municipalities directly under the central government, and the corps medical insurance bureaus. The original text is as follows: This article is selected from the National Medical Insurance Bureau, edited by GMTEight: Chen Wenfang.